A subsidiary of Bayer AG, the Germany-based pharmaceutical company, has filed suit in federal court in Wilmington against Glenmark Generics, an international generic-drug manufacturer, seeking to stop the Mumbai, India-based company from selling a generic form of a medication used to treat a skin disorder.
Glenmark applied for U.S. Food and Drug Administration approval for a generic version of Finacea, a gel used to treat the skin condition rosacea. But the Bayer subsidiaries, Intendis and Intraserv, said they will suffer "irreparable harm for which they have no adequate remedy at law" if Glenmark is allowed to manufacture and sell the drug before Bayer’s patent (U.S. Patent No. 6,534,070, known as the ’070 patent) expires in 2018.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
